Diabetic kidney disease (DKD) is a devastating and frequent complication of diabetes mellitus. Here, we first adopted methylenetetrahytrofolate reductase (MTHFR) gene C677T polymorphism as an instrument to infer the possible causal relevance between circulating homocysteine and DKD risk in a Chinese population and next attempted to build a risk prediction model for DKD. This is a hospital-based case-control association study. Total 1107 study participants were diagnosed with type 2 diabetes mellitus, including 547 patients with newly diagnosed and histologically confirmed DKD. MTHFR gene C677T polymorphism was determined using the TaqMan method.
| MATERIAL S AND ME THODS

| Study participants
This is a hospital-based case-control association study conducted at the China-Japan Friendship Hospital between August 2016 and February 2018. In total, 1107 participants who were diagnosed with type 2 diabetes mellitus were recruited and hospitalized.
Diabetic kidney disease was diagnosed according to the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF-K/DOQI) guidelines. Patients with type 2 diabetes mellitus who had newly diagnosed and histologically confirmed DKD were classified as the case group (n = 547). The rest 560 patients who had experienced type 2 diabetes mellitus for seven or more years and had no history of DKD and severe kidney diseases formed the control group.
The conduct of this study was approved by the institutional review boards of the China-Japan Friendship Hospital. All study participants signed informed consent prior to blood sampling for genetic analysis and all of the other procedures associated with this study.
| Eligibility criteria
Participants in the case group were included if they had a clinical diagnosis of type 2 diabetes mellitus and 24 hours urinary albumin >500 mg/L or an albumin creatinine ratio (ACR) >30 mg/g and participants were excluded if they had no previous history of kidney diseases or if they had primary or secondary kidney diseases that caused proteinuria, such as IgA nephropathy, membranous nephropathy, lupus nephritis, obstructive renal disease and acute urinary tract infection.
Participants in the control group were included if they had a clinical diagnosis of type 2 diabetes mellitus and ACR <30 mg/g. The exclusion criteria were same as the case group.
| Data collection
Each participant was invited to complete a self-designed structured questionnaire to obtain information on age, sex, bodyweight, body height and smoking habit, hypertension and duration of diabetes mellitus. Body mass index (BMI) was calculated as weight (kg) divided by height squared (m 2 ).
Laboratory biomarkers including 24 hours urinary albumin excretion and ACR, high-density lipoprotein cholesterol (HDLC), low-density lipoprotein cholesterol (LDLC), total cholesterol (TC), triglyceride, hemoglobin A1c (HbA1c) and homocysteine were assayed. Serum concentrations of fasting triglyceride, TC, HDLC, LDLC and homocysteine were measured using an automated biochemical analyzer (AU5800 Clinical Chemistry System; Beckman Coulter, Brea, CA). HBA1c was measured using the D-10 Hemoglobin Testing System (Bio-Rad, Hercules, CA).
| Genomic DNA extraction and genotyping
Genomic DNA was extracted from whole blood according to the manufacturer's recommendations and quantified using the NanoDrop 1000 spectrophotometer (ThermoScientific). DNA samples were frozen at −20°C until the time of analysis.
MTHFR gene C677T polymorphism was determined using the TaqMan SNP Genotyping Assay (Applied Biosystems) using the primer sequences: F: 5′-GGC TGA CCT GAA GCA CTT GAA-3′ and R: 5′-AGA AAA GCT GCG TGA TGA TGA A-3′. The probe sequences were: FAM-5′-TCT GCG GGA GTC G-3′-MGB; VIC-5′-CTG CGG GAG CCG A-3′-MGB.
The primers and probes were designed by Applied Biosystems. To verify the genotypes, 50 polymerase chain reaction (PCR) products were randomly selected for DNA sequencing using the ABI 3500 Genetic Analyzer (Applied Biosystems) and the results were 100% concordant. The −2 Log likelihood ratio test was used to compare the fit of two models. The goodness of fit of the model was justified using the Hosmer-Lemeshow test. The receiver operating characteristic (ROC) curves were plotted for models with and without significant factors.
| Statistical analysis
The Sobel-Goodman mediation test was performed to test whether a mediator carried the influence of homocysteine on DKD risk. The net benefits of adding significant factors to basic model were seen by using decision curve analysis. 14 Finally, a nomogram was plotted for significant factors using regression modelling strategies (rms) program in the r software version 3.5.0.
A two-sided P less than 0.05 was considered the threshold of statistical significance. Unless otherwise stated, statistical analysis was completed using the stata/se software version 14.0 (StataCorp., College Station, TX). Figure 1 presents the correlation plot of homocysteine and four blood lipids. The correlation coefficient of circulating homocysteine with lipids ranged from 0.006 to 0.027, with no detectable significance. In addition, the Sobel-Goodman mediation test failed to reveal any significant contribution of BMI and four blood lipids to the relevance between circulating homocysteine concentrations and DKD risk (Table S1 ).
| RE SULTS
| Baseline characteristics
| Correlation between homocysteine and four lipids
| Mendelian randomization estimate
Based on the risk estimates of genotype-phenotype and genotypedisease associations and under the rationales of Mendelian randomization approach, the odds ratio for DKD relative to diabetes mellitus per 5 μmol/L increment of circulating homocysteine concentrations was 3.86 (95% confidence interval: 1.21-2.05, P < 0.001) implying a potential causal role of homocysteine in the pathogenesis of DKD.
| Selection of significant factors
Significant factors in association with DKD risk were selected based on the Forward Logistic regression analysis (Table 2) . Three factors, 
| Prediction performance assessment
Prediction models with (full model) and without (basic model) three significant factors differed significantly and both models showed goodness of fit (Table 3 ).
| Decision curve analysis and nomogram
The benefits gained by adding three significant factors to the basic model were higher than the benefits of the basic model ( Figure 2 ).
Based on three significant factors, a nomogram is plotted in Figure 3 to predict the risk of DKD relative to diabetes mellitus. The C-index of this nomogram to assess prediction accuracy was 0.71 (P < 0.01) indicating good prediction performance. and discriminatory capability. To our knowledge, this is the first Mendelian randomization study that has provided support for a causal role of circulating homocysteine in the pathogenesis of DKD.
| D ISCUSS I ON
Homocysteine is a sulphur-containing non-proteinogenic amino acid biosynthesized from methionine and abnormal elevation of circulating homocysteine concentrations has been implicated in the development of many clinical end-points or pathological conditions, such as cardiovascular disease, 15 stroke 16 and microalbuminuria. 17 Hyperhomocysteinaemia is an independent risk factor for glomeruloslerosis and renal insufficiency and the association of circulating homocysteine with DKD was widely evaluated in the medical literature, yet the results are not often reproducible. [7] [8] [9] [18] [19] [20] [21] [22] Actually, current evidence linking homocysteine to DKD is mainly based on observational data, in which the degree of possible confounding and reverse causation may cloud the true relationship. 23, 24 In this context, Mendelian randomization has proven to be a valuable method to overcome confounding and reverse causality 25, 26 and this method enables estimation of causal relationship in observational studies using genetic alterations as instruments. 27 Following the principles of Mendelian randomization, we found that per 5 μmol/L increment in circulating homocysteine
concentrations increased approximately four-fold the odds of having DKD. This finding was relatively convincing, as the instrumental polymorphism (C677T) selected in this study was simultaneously and significantly associated with circulating homocysteine changes and DKD risk by many studies 11, [28] [29] [30] [31] and further the association between homocysteine and DKD risk was not mediated by obesity and blood lipids. For practical reasons, there is potential clinical utility in the consideration of homocysteine concentrations among diabetic patients.
In support of our findings, peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist ciglitazone can protect DKD in part by activating PPAR-γ and clearing glomerular tissue homocysteine. 32 Pending prospective reproducible investigations circulating homocysteine concentrations can help identify diabetic patients with a high risk of DKD who could benefit from closer monitoring. Nevertheless, we agree that it is of clinical importance to replicate this risk prediction model in other independent groups and refine risk-assessment algorithms with more desired accuracy.
Finally, it is important to consider the potential limitations of this study. First, we recruited study participants at a mono-site, which may limit the generalizability of our findings, although it facilitates consistency of diagnosis and evaluation. Second, only one polymorphism in MTHFR gene was selected as an instrumental variable and it is of added interest to interrogate the suitability of other functional polymorphisms, such as A1298C. 11 Third, given the small number of study participants, we were unable to perform further subgroup analyses such as by sex and smoking habit.
Fourth, we only tested the mediation effect of obesity and four blood lipids and it is unclear whether other important contributing factors might mediate the association of circulating homocysteine with DKD risk. Moreover, it would be more interesting to detecting homocysteine concentrations in urinary samples, which are not available for us. Fifth, our findings were exclusively derived from a Chinese population and external replication would be necessary.
Despite these limitations, our findings provide evidence that elevated circulating homocysteine concentrations were causally associated with an increased risk of DKD in Chinese diabetic patients.
Moreover, we have built a powerful risk prediction model, including homocysteine, hypertension and triglyceride, which can allow early detection and targeted treatment in the control of DKD. For practical reasons, we hope this study will not remain just another endpoint of research instead of a start to establish fundamental data to further explore the molecular mechanisms of circulating homocysteine and DKD.
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